Navigation Links
For the First Time, a Glioma ¨C Brain Cancer ¨C may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing
Date:12/17/2009

that stimulates the innate immune system, as a messenger, it transfers "the information of cancer cell - antigen" to "the killers of the immune system - the T cells," and then T cells can recognize and lyse cells bearing those antigens. "We educate the DC with the brain CSCs, and then conduct the specific immune response which targets the CSCs."

Dr. Dinggang Li: Comprehensive Cancer Therapies

"The outcome of the first pilot study with Johnsen is amazing. The PET-CT scan for Johnsen shows that all the tumor disappeared after the treatment," says Dr. Dinggang Li, M.D. PhD. He has developed and conducted CCT for more than 100 international cancer patients in the past few years. DCs loaded with different kinds of brain cancer related antigens that target cancer cells and the CIK cell treatment are the main elements of his comprehensive treatment for cancer. "In the first cycle of treatment, we treated him with comprehensive approaches including SHG-44 loading DC, CIK cell therapy and TCM, but we had not been able to control the progression of the disease, the tumors continued to grow. We gave him the DC therapy which targets brain CSCs in the 2nd cycle of treatment, and it showed a very promising response."

Dr. Cindy HAO: More clinical trials to confirm the outcome

Cindy HAO, M.D., CEO of Cellonis Biotechnologies is optimistic for the future of this new brain cancer approach. "It gives us a strong confidence to make more efforts toward this direction. This pilot treatment study shows us that the activated immune system can directly kill tumor stem cells as well as tumor daughter cells. But first of all we need to extend our further clinical trials to confirm the outcome. And it also tells us that the future vaccination therapies may be targeted toward Cancer Stem Cell Lysates to improve the antigen-presenting DC response."

    For more information, please contact:

     Urs. J. Lienert, M.B.A.
'/>"/>
SOURCE Cellonis Biotechnologies
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
4. Genmab Announces 2007 First Half Year Results
5. Pharsight Achieves First License Sale for Public-Source Database
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. China Medical Technologies Reports First Quarter Financial Results
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , June 1, 2015  Novartis is ... study of CTL019, an investigational chimeric antigen receptor ... in the treatment of specific types of hard-to-treat ... by the University of Pennsylvania,s Perelman School of ... (r/r) diffuse large B-cell lymphoma (DLBCL) and follicular ...
(Date:6/1/2015)... IL (PRWEB) June 01, 2015 ... developing and manufacturing of chiral stationary phases (CSPs) ... options for its current and presenting solutions for ... to its portfolio. This valuable addition to its ... and effective advantage that can tackle projects for ...
(Date:6/1/2015)... 1, 2015  Boston-based Veritas Genetics is launching ... and bring personalized medicine and prevention to the ... their health. Beginning with its first product, a ... risk, Veritas Genetics is making its products affordable ... amount of genetic data which will be shared ...
(Date:6/1/2015)... MD (PRWEB) June 01, 2015 ... they have entered into a commercial collaboration agreement ... companies will combine their technologies and work together ... (MSC) regenerative technology. RoosterBio and Sistemic will collaborate ... technologies to build more precise and relevant characterization ...
Breaking Biology Technology:Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6Regis Technologies Offers Chiral Chromatography Service 2Regis Technologies Offers Chiral Chromatography Service 3Veritas Genetics To Advance Precision Medicine And Disease Prevention 2Veritas Genetics To Advance Precision Medicine And Disease Prevention 3Sistemic and RoosterBio Inc Announce Broad Collaboration Agreement to Advance miRNA and Mesenchymal Stem/Stromal Cell (MSC) Regenerative Technology 2Sistemic and RoosterBio Inc Announce Broad Collaboration Agreement to Advance miRNA and Mesenchymal Stem/Stromal Cell (MSC) Regenerative Technology 3Sistemic and RoosterBio Inc Announce Broad Collaboration Agreement to Advance miRNA and Mesenchymal Stem/Stromal Cell (MSC) Regenerative Technology 4
... Technologies LLC (Myriant), a privately-held, biotech developer and ... its Science Advisory Board and the appointment of ... will provide broad insight into all aspects of ... feedstocks into valuable chemicals. , (Logo: ...
... N.C., Oct. 21 Cornerstone Therapeutics Inc. (Nasdaq CM: ... and commercializing significant products primarily for the respiratory and ... conference call at 8:30 AM ET on Wednesday, November ... quarter ended September 30, 2009. Management will also ...
... ... business models capture investors, interest. , ... Miami, FL (PRWEB) October 21, 2009 -- iLife Americas, LLC, a ... in the U.S. to market its line of iLife wellness and therapeutic products. Officially ...
Cached Biology Technology:Myriant Technologies LLC Announces Appointment of Science Advisory Board Members 2Myriant Technologies LLC Announces Appointment of Science Advisory Board Members 3Cornerstone Therapeutics to Host Third Quarter 2009 Conference Call 2Cornerstone Therapeutics to Host Third Quarter 2009 Conference Call 3iLife Americas, LLC Enters U.S. Wellness and Therapeutic Markets 2
(Date:5/21/2015)... -- According to a new market ... Services), by Applications (Surveillance (Airborne, Maritime, Land), Threat ... & Defense & Commercial) - Global Forecast to ... expected to grow from $7252.0 Million in 2015 ... Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/19/2015)... YORK , May 19, 2015  Technology is ... both internally and in the cloud. Passwords and their ... use of OTP and standards-based specifications such as those ... the outmoded use of passwords presents for BYOD, COPE, ... a unified biometric identity protocol. In ...
(Date:5/11/2015)... 2015  Synaptics Incorporated (NASDAQ: SYNA ), ... announced the appointment of Wajid Ali ... reporting to Rick Bergman , President and ... Officer, Kathleen Bayless , who announced her ... Ali brings extensive financial management expertise to Synaptics, ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... and the Veterans Affairs Greater Los Angeles Healthcare System ... the cost-effectiveness of current modern drugs for treating hepatitis ... Published in the May 17 Annals of Internal Medicine, ... decisions. Researchers note that a degree of uncertainly exists ...
... known for a long time that only 2% -- 3% ... of our genomes -- often referred to as junk DNA ... RNA, reverse-transcribed into DNA, and then reinserted into a new ... class of these retroelements. Retroviruses can insinuate themselves into the ...
... Don't miss out the cool movies, link at the end ... Medicine researchers have found a way to exercise a little ... their wings, and fly on command by triggering genetic "remote ... central nervous systems, according to a new report in the ...
Cached Biology News:UCLA study assesses cost-effectiveness of Hepatitis B drugs 2UCLA study assesses cost-effectiveness of Hepatitis B drugs 3Chimp genome reveals a retroviral invasion 2Chimp genome reveals a retroviral invasion 3Remote control flies? Fly behavior controlled by laser light 2Remote control flies? Fly behavior controlled by laser light 3
...
5 minutes from gel band to purified DNA...
Sterile concentration of Dithiothreitol (DTT) solution in phosphate buffer (pH 7.0). Dilute contents in one vial (10- fold) to 100 ml. For use in liquefying sputum samples....
...
Biology Products: